• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Impel NeuroPharma Inc.

Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation

April 25, 2022 By Sean Whooley

Impel Neuropharma logo updated

Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Impel NeuroPharma Inc., Impel Pharmaceuticals

Impel NeuroPharma prices $45M offering following FDA approval for migraine treatment

September 10, 2021 By Sean Whooley

Impel Neuropharma logo updated

Impel NeuroPharma (NSDQ:IMPL) announced that it priced an underwritten public offering of common stock worth $45 million. The offering includes 3 million shares of common stock priced to the public at $15 per share, with gross proceeds set to total $45 million before deducting underwriting discounts and commissions and other offering expenses payable by Impel […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

FDA approves Impel NeuroPharma’s nasal spray for treating migraines

September 3, 2021 By Sean Whooley

Impel Neuropharma logo updated

Impel NeuroPharma (NSDQ:IMPL) announced today that the FDA approved its Trudhesa nasal spray for treating migraine in adults. Seattle-based Impel NeuroPharma plans to launch Trudhesa commercially early next month. The company’s shares took a massive hit, though, dropping -19.3% at $18.65 per share by market close and continuing to slide down -0.8% at $18.50 after […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Regulatory/Compliance Tagged With: FDA, Impel NeuroPharma Inc.

Impel NeuroPharma raises $68m for CNS drug-device tech

December 6, 2018 By Sarah Faulkner

Impel Neuropharma logo updated

Impel NeuroPharma said today that it raised $67.5 million in a Series D financing round, with investments from KKR, Norwest Venture Partners, Vivo Capital, 5Am Ventures and venBio Partners. The Seattle-based company plans to use the round’s proceeds to support clinical development efforts for its intranasal drug-delivery device technology. Impel’s INP104 product is in a Phase […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Neurological, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

Impel NeuroPharma readies trial for intranasal drug-device migraine treatment

June 22, 2018 By Sarah Faulkner

Impel NeuroPharma

Impel NeuroPharma said today that the FDA gave it the green light to proceed with its Phase III clinical trial of INP104 – a drug delivered by Impel’s intranasal delivery device for the treatment of acute migraine. The company expects to start enrolling patients in the pivotal trial in the second half of this year. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Impel NeuroPharma Inc.

Impel NeuroPharma touts proof-of-concept trial for intranasal migraine drug

February 7, 2018 By Sarah Faulkner

Impel NeuroPharma

Privately-held biotech Impel NeuroPharma touted positive results today from a Phase I trial of its acute migraine headache therapy. The Seattle-based company’s drug is delivered intranasally using its Precision Olfactory Delivery device, which is designed to deliver drugs to the upper nasal cavity and target the brain using the olfactory and trigeminal nerves. The proof-of-concept […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

Impel NeuroPharma closes $36m series C round for intranasal CNS treatments

December 2, 2016 By Sarah Faulkner

Impel NeuroPharma

Impel NeuroPharma Inc. said today that it closed a $36 million series C financing round to fund its pipeline of precision olfactory delivery (POD) intranasal devices. Life science firms venBIO, 5AM Ventures and Vivo Capital made investments in the round. Seattle-based Impel will get $21 million upfront and $15 million after it reaches development and […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Neurological, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS